Jiří Beneš
Research Subjects
Jiří Beneš has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
- Olga Džupová
Third Faculty of Medicine, Charles University, and University Hospital Bulovka, Prague, Czech Republic
13 shared publications Patty Kostkova
City eHealth Research Centre, C332 City University , London , UK
4 shared publications- Tereza Koprivová Herotová
Third Faculty of Medicine, Bulovka University Hospital , Budinova 2, 180 81 Prague , Czech Republic
4 shared publications - Anna Olczak-Pienkowska
Department of Public Health, Epidemiology and Vaccinology, Military Institute of Medicine—National Research Institute, 04-141 Warsaw, Poland
3 shared publications António Brito Avô
10 Centro de Saúde de Oeiras, Av Salvador Allende , Oeiras, 2780 Oeiras , Portugal
3 shared publicationsCarla Rodriguez Caballero
3 shared publications
Latest Publications
- Open Access
- 6 October 2025
- Published by Czech Society of Cardiology in Cor et Vasa
- Vol. 67 (4) , 449-456
(Blood sampling for culture and interpreting microbiological findings at suspicion of infective endocarditis)
Hemokultivace je spolu s echokardiografi? z?kladn?m vy?et?en?m u??van?m v diagnostice infek?n? endokarditidy. V ?l?nku jsou shrnuty principy spr?vn?ho odb?ru krve ke kultivaci, od klasick?ch z?sad a? k modern?mu p??stupu, jen? spo??v? v jednor...
- 6 October 2025
- Published by Czech Society of Cardiology in Cor et Vasa
- Vol. 67 (4) , 449-456
Open Access(Blood sampling for culture and interpreting microbiological findings at suspicion of infective endocarditis)
Hemokultivace je spolu s echokardiografi? z?kladn?m vy?et?en?m u??van?m v diagnostice infek?n? endokarditidy. V ?l?nku jsou shrnuty principy spr?vn?ho odb?ru krve ke kultivaci, od klasick?ch z?sad a? k modern?mu p??stupu, jen? spo??v? v jednor...
- 15 September 2025
- Published by Springer Nature in Bratislava Medical Journal
- Vol. 126 (11) , 2983-2990
Severe-Complicated Clostridioides difficile Infection: Comments to the Current ESCMID Guidelines
- 15 September 2025
- Published by Springer Nature in Bratislava Medical Journal
- Vol. 126 (11) , 2983-2990
Severe-Complicated Clostridioides difficile Infection: Comments to the Current ESCMID Guidelines
- Open Access
- 20 December 2024
- Published by Czech Society of Cardiology in Cor et Vasa
- Vol. 66 (6) , 632-643
(Antibiotic therapy of infective endocarditis. Recommended practice guaranteed by the Czech Society of Infectious Diseases, the Czech Society for Medical Microbiology, and the Czech Professional Society of Clinical Pharmacy)
- 20 December 2024
- Published by Czech Society of Cardiology in Cor et Vasa
- Vol. 66 (6) , 632-643
Open Access(Antibiotic therapy of infective endocarditis. Recommended practice guaranteed by the Czech Society of Infectious Diseases, the Czech Society for Medical Microbiology, and the Czech Professional Society of Clinical Pharmacy)
- Open Access
- 20 December 2024
- Published by Czech Society of Cardiology in Cor et Vasa
- Vol. 66 (6) , 645-649
(Antibiotic prophylaxis of infective endocarditis. Recommended practice guaranteed by the Czech Society of Infectious Diseases, the Czech Society for Medical Microbiology, and the Czech Professional Society of Clinical Pharmacy)
- 20 December 2024
- Published by Czech Society of Cardiology in Cor et Vasa
- Vol. 66 (6) , 645-649
Open Access(Antibiotic prophylaxis of infective endocarditis. Recommended practice guaranteed by the Czech Society of Infectious Diseases, the Czech Society for Medical Microbiology, and the Czech Professional Society of Clinical Pharmacy)
- Open Access
- 9 September 2024
- Published by Czech Society of Cardiology in Cor et Vasa
- Vol. 66 (4) , 455-465
(Critical comments on the document "2023 ESC Guidelines for the Management of Endocarditis")
?l?nek obsahuje kritiku Doporu?en?ho postupu pro l??bu endokarditidy, kter? vydala Evropsk? kardiologick? spole?nost na podzim 2023 a kter? byl p?elo?en do ?e?tiny a vyd?n v ?asopise Cor et Vasa na ja?e 2024. Doporu?en? postup obsahuje ?adu fo...
- 9 September 2024
- Published by Czech Society of Cardiology in Cor et Vasa
- Vol. 66 (4) , 455-465
Open Access(Critical comments on the document "2023 ESC Guidelines for the Management of Endocarditis")
?l?nek obsahuje kritiku Doporu?en?ho postupu pro l??bu endokarditidy, kter? vydala Evropsk? kardiologick? spole?nost na podzim 2023 a kter? byl p?elo?en do ?e?tiny a vyd?n v ?asopise Cor et Vasa na ja?e 2024. Doporu?en? postup obsahuje ?adu fo...
- 1 January 2023
- Vol. 72 (4) , 221-238
Pathogenesis of infections caused by SARS-CoV-2
SARS-CoV-2 primarily causes mucosal infections of the respiratory or intestinal tract. This virus, unlike other viruses responsible for similar mucosal infections, is characterized by an extraordinary ability to modify the immune response at several levels and thus cause a range of clinical complications. These manipulations create a false picture of pyogenic bacterial infection. The course of the disease is mainly determined by the natural mucosal immunity which can stop the virus from multiplying in the early stages of infection before it can exert its influence. COVID-19 has two main clinical forms: mucosal infection (respiratory or intestinal) and pneumonia. Pneumonia is associated with activation of the vascular endothelium and a procoagulant state. Viremia does not belong to the standard course of the disease. Affecting organs other than the lungs - whether during an active infection or later (long covid) - is usually caused by immuno-pathological reactions or hormonal regulation disorders.
- 1 January 2023
- Vol. 72 (4) , 221-238
Pathogenesis of infections caused by SARS-CoV-2
SARS-CoV-2 primarily causes mucosal infections of the respiratory or intestinal tract. This virus, unlike other viruses responsible for similar mucosal infections, is characterized by an extraordinary ability to modify the immune response at several levels and thus cause a range of clinical complications. These manipulations create a false picture of pyogenic bacterial infection. The course of the disease is mainly determined by the natural mucosal immunity which can stop the virus from multiplying in the early stages of infection before it can exert its influence. COVID-19 has two main clinical forms: mucosal infection (respiratory or intestinal) and pneumonia. Pneumonia is associated with activation of the vascular endothelium and a procoagulant state. Viremia does not belong to the standard course of the disease. Affecting organs other than the lungs - whether during an active infection or later (long covid) - is usually caused by immuno-pathological reactions or hormonal regulation disorders.
- 1 September 2022
- Vol. 28 (3) , 77-94
[Updated Czech guidelines for the treatment of patients with colitis due to Clostridioides difficile].
The updated Czech guidelines differ in some aspects from the 2021 guidelines issued by the ESCMID Study Group for Clostridium difficile. The key points of these Czech recommendations may be summarized as follows: • The drug of choice for hospitalized patients is orally administered fidaxomicin or vancomycin. In outpatients with a mild first episode of C. difficile infection, metronidazole can also be used. • If the patient's response to treatment is good and there are no complications, the duration of antibiotic treatment can be reduced (e.g. to 5 days in case of fidaxomicin or to 6-7 days in case of vancomycin). • If oral therapy is impossible, the drug of choice is tigecycline, 100 mg i.v., b.i.d., with initial shortening of the interval between the first and second doses for faster saturation. If the severity of the disease progresses during this antibiotic treatment, it is necessary to access the ileum or cecum, i.e. to perform double ileostomy or percutaneous endoscopic cecostomy, and to instill vancomycin or fidaxomicin lavages. • Fulminant C. difficile colitis should be treated with oral fidaxomicin ± tigecycline i.v. If peristalsis ceases, fidaxomicin should be administered into the ileum or cecum as described above. If sepsis develops, a broad-spectrum beta-lactam antibiotic (piperacillin/tazobactam, carbapenem) i.v. is added to topically administered fidaxomicin instead of tigecycline i.v.; at the same time, colectomy should be considered as the last resort. • To treat first recurrence, fidaxomicin or vancomycin is administered with a subsequent fecal microbiota transplant (FMT) from a healthy donor. For second or subsequent recurrence, administration of fidaxomicin is of little benefit; the therapy of choice is oral vancomycin and subsequent FMT. Prolonged vancomycin or fidaxomicin taper and pulse treatment is appropriate only when FMT cannot be performed.
- 1 September 2022
- Vol. 28 (3) , 77-94
[Updated Czech guidelines for the treatment of patients with colitis due to Clostridioides difficile].
The updated Czech guidelines differ in some aspects from the 2021 guidelines issued by the ESCMID Study Group for Clostridium difficile. The key points of these Czech recommendations may be summarized as follows: • The drug of choice for hospitalized patients is orally administered fidaxomicin or vancomycin. In outpatients with a mild first episode of C. difficile infection, metronidazole can also be used. • If the patient's response to treatment is good and there are no complications, the duration of antibiotic treatment can be reduced (e.g. to 5 days in case of fidaxomicin or to 6-7 days in case of vancomycin). • If oral therapy is impossible, the drug of choice is tigecycline, 100 mg i.v., b.i.d., with initial shortening of the interval between the first and second doses for faster saturation. If the severity of the disease progresses during this antibiotic treatment, it is necessary to access the ileum or cecum, i.e. to perform double ileostomy or percutaneous endoscopic cecostomy, and to instill vancomycin or fidaxomicin lavages. • Fulminant C. difficile colitis should be treated with oral fidaxomicin ± tigecycline i.v. If peristalsis ceases, fidaxomicin should be administered into the ileum or cecum as described above. If sepsis develops, a broad-spectrum beta-lactam antibiotic (piperacillin/tazobactam, carbapenem) i.v. is added to topically administered fidaxomicin instead of tigecycline i.v.; at the same time, colectomy should be considered as the last resort. • To treat first recurrence, fidaxomicin or vancomycin is administered with a subsequent fecal microbiota transplant (FMT) from a healthy donor. For second or subsequent recurrence, administration of fidaxomicin is of little benefit; the therapy of choice is oral vancomycin and subsequent FMT. Prolonged vancomycin or fidaxomicin taper and pulse treatment is appropriate only when FMT cannot be performed.
- Open Access
- 29 October 2020
- Published by MDPI AG in Antibiotics
- Vol. 9 (11) , 748
Disseminated Pelvic Actinomycosis Caused by Actinomyces Naeslundii
Actinomycosis is a chronic bacterial infection characterized by continuous local spread, irrespective of anatomical barriers, and granulomatous suppurative inflammation. Due to its expansive local growth, it can simulate a malignant tumour. Subsequent hematogenous dissemination to distant organs can mimic metastases and further increase suspicion for malignancy. A case of severe disseminated pelvic actinomycosis associated with intrauterine device is described here. The patient presented with a pelvic mass mimicking a tumour, bilateral ureteral obstruction, ascites, multinodular involvement of the liver, lungs and spleen, inferior vena cava thrombosis and extreme cachexia. Actinomycosis was diagnosed by liver biopsy and confirmed by culture of Actinomyces naeslundii from extracted intrauterine contraceptive device (IUD). Prolonged treatment with aminopenicillin and surgery resulted in recovery with moderate sequelae.
- 29 October 2020
- Published by MDPI AG in Antibiotics
- Vol. 9 (11) , 748
Open AccessDisseminated Pelvic Actinomycosis Caused by Actinomyces Naeslundii
Actinomycosis is a chronic bacterial infection characterized by continuous local spread, irrespective of anatomical barriers, and granulomatous suppurative inflammation. Due to its expansive local growth, it can simulate a malignant tumour. Subsequent hematogenous dissemination to distant organs can mimic metastases and further increase suspicion for malignancy. A case of severe disseminated pelvic actinomycosis associated with intrauterine device is described here. The patient presented with a pelvic mass mimicking a tumour, bilateral ureteral obstruction, ascites, multinodular involvement of the liver, lungs and spleen, inferior vena cava thrombosis and extreme cachexia. Actinomycosis was diagnosed by liver biopsy and confirmed by culture of Actinomyces naeslundii from extracted intrauterine contraceptive device (IUD). Prolonged treatment with aminopenicillin and surgery resulted in recovery with moderate sequelae.
- 1 February 2016
- Published by Czech Society of Cardiology in Cor et Vasa
- Vol. 58 (1) , e107-e128
2015 ESC Guidelines for the management of infective endocarditis. Summary document prepared by the Czech Society of Cardiology
- 1 February 2016
- Published by Czech Society of Cardiology in Cor et Vasa
- Vol. 58 (1) , e107-e128
2015 ESC Guidelines for the management of infective endocarditis. Summary document prepared by the Czech Society of Cardiology